Android app on Google Play

Gilead (GILD) Q4 Sovaldi Sales Tracking at $53M - Deutsche Bank

January 3, 2014 2:07 PM EST Send to a Friend
Get Alerts GILD Hot Sheet
Price: $92.92 +1.60%

Rating Summary:
    21 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 24 | New: 8
Trade GILD Now!
Join SI Premium – FREE
Deutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) with a price target of $95.00. Analyst Robyn Karnauskas views week 3 scripts as strong despite the holiday, and said Q4 sales were track at $53 million.

"IMS recently released wk #3 scripts for Sovaldi and our calculations indicate US 4Q’13 sales $53M. Consensus is modeling 4Q numbers at $73M. Second week new patient starts were 797 vs. 834 in wk #2. This figure does not include wholesale inventory. The slight decline is likely due to Xmas. For comp, we note that Wk #3 numbers for Incivek were 457 while it was 321 for Victrelis. At peak, weekly NRx number was 1445 for Incivek (wk #23) & 465 for Victrelis (wk #17).These Sovaldi trends are very early in the launch as we just have three week of scripts," said Karnauskas.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $75.21 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Deutsche Bank

Add Your Comment